Search

Background: Irritable bowel syndrome (IBS) is one of the most frequent and recurrent gastrointestinal diseases. However, up to now, no pharmacological agent has been approved to treat IBS. Emerging evidence showed that inflammation has a vital role in enhancing nervous system sensitivity and perception of abdominal pain in subjects with IBS. Propolis is an herbal substance with a broad spectrum of antioxidants, anti-inflammatory, and prebiotic properties, which might exert beneficial effects to reduce the severity of IBS. The current clinical trial aims to evaluate the efficacy of propolis supplementation on IBS.Methods: This single-center, randomized, double-blind, placebo-controlled clinical trial will be performed to evaluate the effect of propolis supplementation in adult patients with IBS diagnosed with Rome IV criteria. Fifty-two eligible patients will randomly be allocated to receive a propolis tablet (450 mg, containing 100 mg polyphenol compounds) or identical placebo, twice daily for 6 weeks. The primary outcome of the trial is an improvement in IBS severity from baseline to the sixth week of intervention. The secondary outcomes include the change in weight, waist circumference, and IBS quality of life. We will use the paired sample t test or Mann-Whitney U test for the within-group comparison and independent sample t test or Wilcoxon rank-sum and chi-square test or Fisher's exact test for the between-group comparison. Besides, a multivariable-adjusted mean effect will be computed using the ANCOVA test.Discussion: We hypothesize that propolis supplementation would be useful for treating IBS through its antioxidants, anti-inflammatory, and prebiotic properties. This trial will show the results of propolis supplementation, whether positive or negative, on IBS. If the current trial confirms our hypothesis, propolis supplementation can be a new choice in adjunctive therapy of IBS.Trial Registration: Iranian Registry of Clinical Trials IRCT20190708044154N1. Registered on 26 December 2019. Updated on 13 February 2020. https://en.irct.ir/trial/40983 SPONSOR: Tabriz University of Medical Sciences, Tabriz, Iran. [ABSTRACT FROM AUTHOR]

Objectives: In this study, we investigate the effect of boron-containing compounds and oleoylethanolamide supplementation on the recovery trend in patients with COVID-19.Trial Design: The current study is a single-center, randomized, double-blind, placebo-controlled clinical trial with parallel groups.Participants: The inclusion criteria include male and female patients≥18 years of age, with a confirmed diagnosis of SARS-CoV-2 infection via polymerase chain reaction (PCR) and/or antibody test and with written informed consent to participate in this trial. The exclusion criteria include regular use of any other supplement, severe and critical COVID-19 pneumonia, pregnancy and breastfeeding. This study is being conducted at Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.Intervention and Comparator: Patients are randomly assigned to four groups. The first group (A) will take one capsule containing 5 mg of boron compounds twice a day for two weeks. The second group (B) will take one capsule containing 200 mg oleoylethanolamide twice a day for two weeks. The third group (C) will take one capsule containing 5 mg boron compounds with 200 mg oleoylethanolamide twice a day for two weeks, and the fourth group (D) does not receive any additional treatment other than routine treatments. Boron-containing compounds and oleoylethanolamide capsules will be synthesized at Nutrition Research Center of Tabriz University of Medical Sciences.Main Outcomes: The primary end point of this study is to investigate the recovery rate of clinical symptoms, including fever, dry cough, and fatigue, as well as preclinical features, including complete blood count (CBC), the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) profiles within two weeks of randomization.Randomisation: Patients are randomized into four equal groups in a parallel design (allocation ratio 1:1). A randomized block procedure is used to divide subjects into one of four treatment blocks (A, B, C, and D) by a computer-generated allocation schedule.Blinding (masking): The participants and investigators (enrolling, assessing, and analyzing) are blinded to the intervention assignments until the end of the study and data analysis.Numbers To Be Randomised (sample Size): The calculated total sample size is 40 patients, with 10 patients in each group.Trial Status: The protocol is Version 1.0, May 17, 2020. Recruitment began May 19, 2020, and is anticipated to be completed by October 19, 2020.Trial Registration: This clinical trial has been registered by the title of "Assessment of boron-containing compounds and oleoylethanolamide supplementation on the recovery trend in Patients with COVID-19: A double-blind randomized placebo-controlled clinical trial" in the Iranian Registry of Clinical Trials (IRCT). The registration number is " IRCT20090609002017N35 ", https://www.irct.ir/trial/48058 . The registration date is 17 May 2020.Full Protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. [ABSTRACT FROM AUTHOR]

Background: Diabetes mellitus is a disease characterized by high glucose level resulting from defects in insulin secretion, insulin action, or both. Prevalence of diabetes increases with increasing age and its prevalence in adults is slightly higher in women than in men. Diabets mellitus is one of the most important risk factors for coronary heart disease. Objectives: The present study was conducted to determine food habits and their correlation with serum lipid profiles in diabetics patients (Type II) at Sina and Asadabadi Hospitals affiliated to Tabrize Medical Science University-Iran. Method: 118 diabetic patients (89 women and 29 men) aged 52 ± 10 years old were selected by simple random sampling at two Hospital of Tabriz. Food patterns were estimated by using of 24 hour recall for three consecutive days and daily nutrient intake was calculated by using food composition software. Daily energy and nutrient intakes were compared with RDA. We determined their correlation with serum lipids profile by using correlation test. Result: Mean ± SE of energy (Kcal), carbohydrate (gr), protein (gr), fat (gr), fibre (gr), cholesterol (mg), saturated fatty acid (gr), monounsaturated fatty acid (gr), and polyunsaturated fatty acid (gr) were 95.68 ± 2.68, 103.27 ± 2.55, 115.95 ± 3.42, 73.43 ± 2.60, 80.03 ± 3.55, 67.26 ± 5.30, 58.72 ± 2.21, 56.61 ± 4.14 and 47.57 ± 3 respectively. Mean ± S.E of fasting blood sugar (mg/dl), 2 hours plasma glucose level (mg/dl) cholesterol (mg/dl), triglyceride (mg/dl) and high density lipoproteins (mg/dl) were 178.47 ± 7.19, 272.62 ± 8.58, 229.66 ± 4.96, 271.74 ± 20.33 and 49.16 ± 3.53 respectively. We found that daily energy, total fat, and cholesterol intake had direct correlation with serum lipids (P<0.05). There were no other significant correlations between daily nutrient intakes with serum lipids. Conclusion: Based on the results of present study, education about decreasing daily calorie and any kind of fat intake emphasized. [ABSTRACT FROM AUTHOR]